日本山口大學(xué)科學(xué)家嘗試用去除體內(nèi)鐵離子的方法，治療肝癌,，取得一定成效,。
據(jù)日本《讀賣新聞》日前報(bào)道，山口大學(xué)教授坂井田功等科學(xué)家嘗試向肝癌晚期患者的肝臟中直接注射鐵螯合劑,。結(jié)果發(fā)現(xiàn),，在接受2個(gè)月左右的注射后，參加試驗(yàn)的10名肝癌晚期患者中有2人的腫瘤組織有所縮小,，另有3人的病情停止惡化,。
鐵螯合劑能夠與人體內(nèi)的鐵離子結(jié)合，隨著尿液一同排出,，注射鐵螯合劑能夠有效降低體內(nèi)的鐵離子濃度,。因?yàn)殍F離子是肝癌等腫瘤組織發(fā)育過程中的一種重要原料，因此體內(nèi)鐵離子濃度下降,，對(duì)于肝癌有一定的治療作用,。
科學(xué)家說，目前的臨床試驗(yàn)顯示,，去鐵有可能成為一種治療肝癌的新療法,。不過，由于身體失去鐵離子有很大的風(fēng)險(xiǎn)性,，日本科學(xué)家認(rèn)為準(zhǔn)確使用這一方法仍需更多的試驗(yàn)數(shù)據(jù),。
日本科學(xué)家的上述成果已發(fā)表在美國《新英格蘭醫(yī)學(xué)雜志》上。(生物谷 Bioon.com）
doi:N Engl J Med 2011; 365:576-578
PMC:
PMID:
Deferoxamine for Advanced Hepatocellular Carcinoma
Takahiro Yamasaki,Shuji Terai，Isao Sakaida,
Deferoxamine was administered an average of 27 times (range, 9 to 78). Two, three, and five patients had a partial response, stable disease, and progressive disease, respectively (according to the Eastern Cooperative Oncology Group criteria). The overall response rate was 20%.
Tumor-marker levels (alpha-fetoprotein, des-γ-carboxyprothrombin, alpha-fetoprotein L3, or all of these levels) decreased in patients with a partial response. In one patient, a massive hepatocellular tumor with lung metastases disappeared with deferoxamine treatment (Figure 1Figure 1
Deferoxamine Treatment in One Patient.). The 1-year cumulative survival rate was 20%. Four patients had grade 2 or 3 interstitial pneumonia (according to the Common Terminology Criteria for Adverse Events, version 4.0), and one patient had grade 2 renal dysfunction. However, no grade 4 adverse events were observed.
Sorafenib, a multikinase inhibitor, has recently been established as the standard of care for patients with advanced hepatocellular carcinoma and preserved liver function (Child–Pugh class A) because it increases survival.5 However, its safety and efficacy for patients with Child–Pugh class B or C disease is still unknown. Deferoxamine may warrant testing in patients with Child–Pugh class B or C hepatocellular carcinoma.
